XBiotech (XBIT) Current Deferred Revenue (2019 - 2020)

XBiotech (XBIT) posted Current Deferred Revenue of $1.5 million for Q2 2020, little changed on a QoQ basis from $1.5 million in Q1 2020.

Analysis

XBiotech (XBIT) Current Deferred Revenue (2019 - 2020) Analysis & Trends

XBiotech has reported Current Deferred Revenue for 2 years, with the latest figure at $1.5 million in Q2 2020.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $1.5 million in Q2 2020; TTM through Jun 2020 was $1.5 million, a N/A change from a year earlier, with the FY2019 full-year figure at $4.5 million, changed N/A from the prior year.
Current Deferred Revenue was $1.5 million for Q2 2020 at XBiotech, roughly flat from $1.5 million in the prior quarter.
The five-year high for Current Deferred Revenue was $4.5 million in Q4 2019, with the low at $1.5 million in Q1 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn
10	XBiotech	66.16 Mn	66.16 Mn	-

Historic Data

Download Data